CME/CE

Episodes 129-144 of 146

• 

  MinuteCE®

  Next-Generation TKI Therapy for ROS1-Rearranged NSCLC

  1.00 credit 9 episodes

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 credit 9 episodes

• 

  RestartResume

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  RestartResume

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  MinuteCE®

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  RestartResume

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  MinuteCE®

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  RestartResume

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  MinuteCE®

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  Intracranial Activity of ROS1 TKIs

  RestartResume

  Intracranial Activity of ROS1 TKIs

  MinuteCE®

  Intracranial Activity of ROS1 TKIs

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  1.00 program credit

• 

  RestartResume

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  RestartResume

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  MinuteCE®

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  RestartResume

  Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  MinuteCE®

  Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  1.00 program credit

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  RestartResume

  First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  MinuteCE®

  First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  1.00 program credit

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  RestartResume

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  MinuteCE®

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  1.00 program credit

• 

  RestartResume

  What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

  RestartResume

  What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

  MinuteCE®

  What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

  1.25 program credits

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

  MinuteCE®

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  MinuteCE®

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  RestartResume

  Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

  RestartResume

  Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

  MinuteCE®

  Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

  1.25 program credits

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  MinuteCE®

  Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies

  1.25 credits 11 episodes

  • 

    

    Yelena Janjigian, MD

  • 

    

    Samuel J. Klempner, MD

  1.25 credits 11 episodes

• 

  RestartResume

  HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

  RestartResume

  HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

  MinuteCE®

  HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  RestartResume

  Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

  RestartResume

  Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

  MinuteCE®

  Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• Previous
• 1
• 2
• …
• 7
• 8
• 9
• 10
• Next